Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 20/20 | 0.82 |
| ▸ | ELOC | Q15369 | 7/20 | 0.53 |
| ▸ | ELOB | Q15370 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21741885 | 0.90 | VHL (1.00) | VHLELOCELOB | |
| SCHEMBL26497908 | 0.86 | VHL (0.74) | VHLELOCELOB | |
| SCHEMBL18530381 | 0.86 | VHL (0.65) | VHLELOCELOB | |
| SCHEMBL21107299 | 0.83 | VHL (0.69) | VHLELOCELOB | |
| SCHEMBL23320837 | 0.83 | VHL (0.58) | VHLELOCELOB | |
| SCHEMBL25348264 | 0.83 | VHL (0.58) | VHLELOCELOB | |
| SCHEMBL19661696 | 0.82 | VHL (0.67) | VHLELOCELOB | |
| SCHEMBL20111386 | 0.81 | VHL (0.67) | VHLELOCELOB | |
| SCHEMBL15110240 | 0.81 | VHL (0.66) | VHLELOCELOB | |
| SCHEMBL25348347 | 0.81 | VHL (0.55) | VHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230091042-A1 | SMARCA2-VHL DEGRADERS | AMGEN INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
| WO-2021142247-A1 | SMARCA2-VHL DEGRADERS | AMGEN INC. (US) | 2021-07-15 | — | — | WO | disclosed |
| EP-3784665-A1 | PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS | Aurigene Discovery Technologies Limited (IN) | 2021-03-03 | — | — | EP | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| WO-2020200291-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020142228-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | VHL 2471/4885ELOC 874/4885ELOB 451/4885 |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | VHL 2471/4885ELOC 874/4885ELOB 451/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | VHL 2471/4885ELOC 874/4885ELOB 451/4885 |
| US-20230091042-A1 | SMARCA2-VHL DEGRADERS | VHL, SMARCC2, SMARCC1 | VHL 1/4885ELOC 334/4885ELOB 332/4885 |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | VHL 271/4885ELOC 3332/4885ELOB 2891/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | VHL 2471/4885ELOC 874/4885ELOB 451/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | VHL 2471/4885ELOC 874/4885ELOB 451/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | VHL 2471/4885ELOC 874/4885ELOB 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.